Introduction: Although different risk factors for oxaliplatin-associated chronic peripheral neuropathy have been identified and the predictive value of neuroinflammatory cytokines has often been emphasized, a clearly accepted predictive biomarker with economical, reproducible, and easily accessible properties has not yet been identified. In this study, we aimed to determine the relationship between serum uric level measured at the time of diagnosis and oxaliplatin-related peripheral neuropathy, based on literature information on the relationship between diabetic neuropathy and serum uric acid level. Methods: In the study, 166 patients with colon adenocarcinoma, who were clinically thought to have grade 1–2 neuropathy in their follow-up after completing the adjuvant mFOLFOX6 regimen without dose reduction for 6 months, were grouped as those with or without peripheral neuropathy according to electromyography results. Demographic, clinical, laboratory and treatment-related characteristics, as well as serum uric acid levels at diagnosis, were determined as study variables and the groups were compared. Based on the presence of peripheral neuropathy, an ROC curve was drawn for serum uric acid level, cutoff was determined, and multivariable logistic (binary) regression analysis was also applied to determine independent risk factors that may affect peripheral neuropathy. If the p value was below 0.05, it was considered statistically significant. Results: It was determined that 29% of the patients (n = 48) had peripheral neuropathy proven by electromyography. It was determined that the majority of patients with peripheral neuropathy were women, above 65 years of age, low body mass index, high body surface area, and smokers. While the serum uric acid level of all patients was 5.1 mg/dL (1.9–9.1), it was significantly higher in patients with peripheral neuropathy than in those without neuropathy (p = 0.0012). We found that ORPN may develop in patients with SUA levels higher than 5.96 mg/dL in men and 6.04 mg/dL in women at the time of diagnosis, and these cutoff values ​​had a sensitivity of 40% and a specificity of 95.40% in men, respectively, while the sensitivity in women was 84.6% and the specificity was 83.87%. In multivariable analysis, female gender, smoking, high body surface area, and high serum uric acid level were determined to be independent predictors for all patients. Conclusion: Despite the limitations of the study, it was concluded that the possibility of developing oxaliplatin-induced peripheral neuropathy may be high in patients with high serum uric acid levels. This study needs to be repeated prospectively and evaluated in larger cohorts.

1.
van den Boogaard
WMC
,
Komninos
DSJ
,
Vermeij
WP
.
Chemotherapy side-effects: not all DNA damage is equal
.
Cancers
.
2022
;
14
(
3
):
627
.
2.
Hertz
DL
,
Lustberg
MB
,
Sonis
S
.
Evolution of predictive risk factor analysis for chemotherapy-related toxicity
.
Support Care Cancer
.
2023
;
31
(
10
):
601
.
3.
Desforges
AD
,
Hebert
CM
,
Spence
AL
,
Reid
B
,
Dhaibar
HA
,
Cruz-Topete
D
, et al
.
Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: an update
.
Biomed Pharmacother
.
2022
;
147
:
112671
.
4.
Burgess
J
,
Ferdousi
M
,
Gosal
D
,
Boon
C
,
Matsumoto
K
,
Marshall
A
, et al
.
Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms, and treatment
.
Oncol Ther
.
2021
;
9
(
2
):
385
450
.
5.
Seretny
M
,
Currie
GL
,
Sena
ES
,
Ramnarine
S
,
Grant
R
,
MacLeod
MR
, et al
.
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis
.
Pain
.
2014
;
155
(
12
):
2461
70
.
6.
Molassiotis
A
,
Cheng
HL
,
Lopez
V
,
Au
JSK
,
Chan
A
,
Bandla
A
, et al
.
Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy
.
BMC Cancer
.
2019
;
19
(
1
):
132
.
7.
Kaiser
K
,
Lyleroehr
M
,
Shaunfield
S
,
Lacson
L
,
Corona
M
,
Kircher
S
, et al
.
Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: a qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale
.
World J Gastrointest Oncol
.
2020
;
12
(
2
):
205
18
.
8.
Soveri
LM
,
Lamminmaki
A
,
Hanninen
UA
,
Karhunen
M
,
Bono
P
,
Osterlund
P
.
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy
.
Acta Oncol
.
2019
;
58
(
4
):
398
406
.
9.
Brewer
JR
,
Morrison
G
,
Dolan
ME
,
Fleming
GF
.
Chemotherapy-induced peripheral neuropathy: current status and progress
.
Gynecol Oncol
.
2016
;
140
(
1
):
176
83
.
10.
Pachman
DR
,
Qin
R
,
Seisler
DK
,
Smith
EM
,
Beutler
AS
,
Ta
LE
, et al
.
Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III Trial N08CB (Alliance)
.
J Clin Oncol
.
2015
;
33
(
30
):
3416
22
.
11.
Gebremedhn
EG
,
Shortland
PJ
,
Mahns
DA
.
The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review
.
BMC Cancer
.
2018
;
18
(
1
):
410
.
12.
Land
SR
,
Kopec
JA
,
Cecchini
RS
,
Ganz
PA
,
Wieand
HS
,
Colangelo
LH
, et al
.
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: nsabpc-07
.
J Clin Oncol
.
2007
;
25
(
16
):
2205
11
.
13.
Briani
C
,
Argyriou
AA
,
Izquierdo
C
,
Velasco
R
,
Campagnolo
M
,
Alberti
P
, et al
.
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study
.
J Peripher Nerv Syst
.
2014
;
19
(
4
):
299
306
.
14.
National Cancer Institute
.
Common Terminology criteria for adverse events (CTCAE)
. Last Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_60 (accessed date 7 22, 2024).
15.
Kiani
J
,
Habibi
Z
,
Tajziehchi
A
,
Moghimbeigi
A
,
Dehghan
A
,
Azizkhani
H
.
Association between serum uric acid level and diabetic peripheral neuropathy (A case control study)
.
Caspian J Intern Med
.
2014
;
5
(
1
):
17
21
.
16.
Papanas
N
,
Demetriou
M
,
Katsiki
N
,
Papatheodorou
K
,
Papazoglou
D
,
Gioka
T
, et al
.
Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus
.
Exp Diabetes Res
.
2011
;
2011
:
346051
.
17.
Papanas
N
,
Katsiki
N
,
Papatheodorou
K
,
Demetriou
M
,
Papazoglou
D
,
Gioka
T
, et al
.
Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus
.
Angiology
.
2011
;
62
(
4
):
291
5
.
18.
Dovell
F
,
Boffetta
P
.
Serum uric acid and cancer mortality and incidence: a systematic review and meta-analysis
.
Eur J Cancer Prev
.
2018
;
27
(
4
):
399
405
.
19.
Fini
MA
,
Elias
A
,
Johnson
RJ
,
Wright
RM
.
Contribution of uric acid to cancer risk, recurrence, and mortality
.
Clin Transl Med
.
2012
;
1
(
1
):
16
30
.
20.
Du
XJ
,
Chen
L
,
Li
WF
,
Tang
LL
,
Mao
YP
,
Guo
R
, et al
.
Use of pretreatment serum uric acid level to predict metastasis in locally advanced nasopharyngeal carcinoma
.
Head Neck
.
2017
;
39
(
3
):
492
7
.
21.
Stotz
M
,
Szkandera
J
,
Seidel
J
,
Stojakovic
T
,
Samonigg
H
,
Reitz
D
, et al
.
Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients
.
PLoS One
.
2014
;
9
(
8
):
e104730
.
22.
Tanriverdi
O
,
Cokmert
S
,
Oktay
E
,
Pilanci
KN
,
Menekse
S
,
Kocar
M
, et al
.
Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish Descriptive Oncological Researches Group
.
Med Oncol
.
2014
;
31
(
10
):
217
.
23.
Linder
N
,
Butzow
R
,
Lassus
H
,
Lundin
M
,
Lundin
J
.
Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma
.
Gynecol Oncol
.
2012
;
124
(
2
):
311
8
.
24.
Yue
C
,
Feng
P
,
Yao
Z
,
Yu
X
,
Lin
W
,
Qian
YM
, et al
.
High serum uric acid concentration predicts poor survival in patients with breast cancer
.
Clin Chim Acta
.
2017
;
473
:
160
5
.
25.
Yang
S
,
He
X
,
Liu
Y
,
Ding
X
,
Jiang
H
,
Tan
Y
, et al
.
Prognostic significance of serum uric acid and gamma-glutamyltransferase in patients with advanced gastric cancer
.
Dis Markers
.
2019
;
2019
:
1415421
.
26.
Yan
J
,
Zhu
C
.
Hyperuricemia is a adverse prognostic factor for colon cancer patients
.
Int J Gen Med
.
2021
;
14
:
3001
6
.
27.
Szkandera
J
,
Gerger
A
,
Liegl-Atzwanger
B
,
Stotz
M
,
Samonigg
H
,
Ploner
F
, et al
.
Uric acid levels in blood are associated with clinical outcome in soft-tissue sarcoma patients
.
Clin Chem Lab Med
.
2015
;
53
(
3
):
493
7
.
28.
Haam
JH
,
Kim
BT
,
Kim
EM
,
Kwon
H
,
Kang
JH
,
Park
JH
, et al
.
Diagnosis of obesity: 2022 Update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity
.
J Obes Metab Syndr
.
2023
;
32
(
2
):
121
9
.
29.
DuBois
D
,
Du Bois
EF
.
A formula to estimate the approximate surface area if weight and height be known
.
Arch Intern Med
.
1916
;
17
:
863
71
.
30.
Flatters
SJL
,
Dougherty
PM
,
Colvin
LA
.
Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review
.
Br J Anaesth
.
2017
;
119
(
4
):
737
49
.
31.
Vichaya
EG
,
Chiu
GS
,
Krukowski
K
,
Lacourt
TE
,
Kavelaars
A
,
Dantzer
R
, et al
.
Mechanisms of chemotherapy-induced behavioral toxicities
.
Front Neurosci
.
2015
;
9
:
131
.
32.
Becker
BF
.
Towards the physiological function of uric acid
.
Free Radic Biol Med
.
1993
;
14
(
6
):
615
31
.
33.
Hu
DE
,
Moore
AM
,
Thomsen
LL
,
Brindle
KM
.
Uric acid promotes tumor immune rejection
.
Cancer Res
.
2004
;
64
(
15
):
5059
62
.
34.
Gasse
P
,
Riteau
N
,
Charron
S
,
Girre
S
,
Fick
L
,
Pétrilli
V
, et al
.
Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis
.
Am J Respir Crit Care Med
.
2009
;
179
(
10
):
903
13
.
35.
Sempere-Bigorra
M
,
Julian-Rochina
I
,
Cauli
O
.
Chemotherapy-induced neuropathy and diabetes: a scoping review
.
Curr Oncol
.
2021
;
28
(
4
):
3124
38
.
36.
Kaur
S
,
Pandhi
P
,
Dutta
P
.
Painful diabetic neuropathy: an update
.
Ann Neurosci
.
2011
;
18
(
4
):
168
75
.
37.
Zajaczkowska
R
,
Kocot-Kepska
M
,
Leppert
W
,
Wrzosek
A
,
Mika
J
,
Wordliczek
J
.
Mechanisms of chemotherapy-induced peripheral neuropathy
.
Int J Mol Sci
.
2019
;
20
(
6
):
1451
.
38.
Beijers
A
,
Mols
F
,
Dercksen
W
,
Driessen
C
,
Vreugdenhil
G
.
Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy
.
J Community Support Oncol
.
2014
;
12
(
11
):
401
6
.
39.
Alejandro
L
,
Behrendt
CE
,
Chen
K
,
Openshaw
H
,
Shibata
S
.
Predicting acute and persistent neuropathy associated with oxaliplatin
.
Am J Clin Oncol
.
2013
;
36
(
4
):
331
7
.
40.
Yildirim
N
,
Cengiz
M
.
Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin
.
Support Care Cancer
.
2020
;
28
(
10
):
4781
8
.
41.
Tofthagen
C
,
Donovan
KA
,
Morgan
MA
,
Shibata
D
,
Yeh
Y
.
Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors
.
Support Care Cancer
.
2013
;
21
(
12
):
3307
13
.
42.
Velasco
R
,
Alemany
M
,
Villagran
M
,
Argyriou
AA
.
Predictive biomarkers of oxaliplatin-induced peripheral neurotoxicity
.
J Pers Med
.
2021
;
11
(
7
):
669
.
43.
Tofthagen
C
,
Tanay
M
,
Perlman
A
,
Starr
J
,
Advani
P
,
Sheffield
K
, et al
.
A systematic review of nutritional lab correlates with chemotherapy induced peripheral neuropathy
.
J Clin Med
.
2022
;
11
(
2
):
355
.
You do not currently have access to this content.